Ex-Nightstar, Gyroscope and AGTC teams try again for next retinal gene therapy with $120M for Beacon Therapeutics
Life sciences investor Syncona is taking a second shot at X-linked retinitis pigmentosa, this time with Beacon Therapeutics, a retinal gene therapy startup led by former executives of Syncona-backed companies Nightstar Therapeutics and Gyroscope Therapeutics. The…#nightstar #xlrp #biogen #unlock
Source: Reuters: Health - Category: Consumer Health News Source Type: news